Finance entity
markets is the sole category represented across all 2 tracked stories. AxoGen is most often covered alongside Avance Nerve Graft, which appears in 1 of these 2 stories. The 30-day window averages about 0.5 stories each week. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Mar 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 2 tracked stories. AxoGen is most often covered alongside Avance Nerve Graft, which appears in 1 of these 2 stories. The 30-day window averages about 0.5 stories each week. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. At 5, the average consequence score sits below the same-window beat average of 6.3. This profile follows 2 Finance stories mentioning AxoGen across the period from February 21, 2026 to March 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 2396 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AxoGen. Shared-story counts are live from our verified record — not editorial picks.
DAFNA Capital Management reduced its position in Axogen by approximately 265,456 shares during the fourth quarter of 2025, a move valued at $6.53 million. Despite the trim, the hedge fund maintains a significant $15.6 million stake in the nerve-repair specialist, which has seen its stock price climb 71% over the past year.
AxoGen (NASDAQ: AXGN) has received a major boost from Wall Street as Wells Fargo upgraded the nerve-repair specialist to a 'Strong-Buy' rating. The upgrade follows a significant price target hike from Jefferies, signaling a robust consensus on the company's growth potential in the medical technology sector.
AxoGen is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
